Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
RF Van Vollenhoven, JP Buyon, W Stohl… - Annals of the …, 2016 - ard.bmj.com
Objectives To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
JT Merrill, RF van Vollenhoven… - Ann …, 2016 - academicworks.medicine.hofstra …
OBJECTIVES: To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). METHODS …
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). METHODS …
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
JT Merrill, RF van Vollenhoven… - Annals of the …, 2016 - search.proquest.com
Objectives To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
JT Merrill, RF van Vollenhoven, JP Buyon… - Annals of the …, 2015 - ard.bmj.com
Objectives To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
JT Merrill, RF van Vollenhoven… - Annals of the …, 2016 - pubmed.ncbi.nlm.nih.gov
Objectives To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
JT Merrill, RF van Vollenhoven, JP Buyon… - Annals of the …, 2015 - europepmc.org
Objectives To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
[引用][C] Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
JT Merrill, RF van Vollenhoven, JP Buyon… - Annals of the …, 2015 - cir.nii.ac.jp
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating
factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week …
factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week …
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
JT Merrill, RF van Vollenhoven… - Annals of the …, 2016 - researchinformation.amsterdamumc …
Objectives To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …